At the news
? BULLISHIMPACT 8/10 6-K filed Jul 21, 2026 at 08:30 ET
Alpha Tau reported positive clinical data from a study of Alpha DaRT in combination with pembrolizumab in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC). The combination produced a 100% objective response rate (ORR) and a median overall survival of 18.2 months among evaluable patients, significantly exceeding historical benchmarks for pembrolizumab monotherapy (19% ORR, 12.3 months OS). The trial met its pre-specified success criterion, and the company is discussing a larger U.S. study with the FDA, representing a major pipeline catalyst for this pre-revenue oncology company.
- Alpha DaRT plus pembrolizumab produced a 100% objective response rate (ORR) in 9 evaluable patients with HNSCC, vs. ~19% historical benchmark for pembrolizumab monotherapy.
- Median overall survival was 18.2 months, vs. 12.3 months for pembrolizumab monotherapy in KEYNOTE-048.
- Median progression-free survival was 5.4 months, vs. 3.2 months for pembrolizumab monotherapy.
- No Alpha DaRT-related serious adverse events were observed; only two Grade 1 adverse events were reported.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access